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For reprints and permission queries, please visit SAGE's Web site at http://www.sagepub.com/journalsPermissions.nav. Pharmacometrics has expanded far beyond its initially defined focus on the analysis of measurements (metrics) associated with pharmacokinetics and biopharmaceutics.
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1 As an emerging quantitative science, pharmacometrics spans the spectrum from basic research into disease and mechanisms of drug action to the rational use of medicines in patient care. Quantitative modeling and simulation provide the foundation for this multidisciplinary effort that involves basic and applied university researchers, industry drug development scientists and decision makers, government regulatory scientists, clinicians, and other health professionals.
Although the domain of pharmacometrics continues to broaden, three overarching themes are clearly guiding this evolution. These are Integration, Innovation, and Impact: (1) quantitative integration of multisource data and knowledge through the application of clinical, biomedical, biological, engineering, statistical, and mathematical concepts, resulting in (2) continuous methodological and technological innovation enhancing scientific understanding and knowledge, which in turn (3) has an impact on discovery, research, development, approval, and utilization of new medicines. The triplet of IntegrationInnovation-Impact forms a circle of excellence (the logo of this supplement shown above right) that can provide the fuel of self-renewal that is necessary to expand pharmacometrics as a vibrant scientific discipline.
This supplement is organized based on the themes of Integration-Innovation-Impact as outlined in the table of contents. The contributions include commentaries, white papers, reviews, and original research articles. We hope that this issue will stimulate the new thinking necessary to ensure the success and growth of pharmacometrics.
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